AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28249612 — intervention group
Group type: COMPARATOR
Intervention: Control arm with cisplatin chemo‐irradiation, total doses of 70.0 Gy/56.0 Gy with 2.0 Gy and 1.6 Gy.
Number of subjects: 100
Study 28249612 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-study with dose escalation up to 77.0 Gy/70.0 Gy/56.0 Gy with 2.2 Gy/2.0 Gy and 1.6 Gy.
Number of subjects: 100
Study 26530661 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure of eight bandage
Number of subjects: 60
Study 26530661 — intervention group
Group type: COMPARATOR
Intervention: Broad arm sling
Number of subjects: 60
Study 24176010 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg R. crenulata extract
Number of subjects: 102
Study 24176010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 21485103 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions (MSBP)
Number of subjects: 424
Study 21485103 — intervention group
Group type: COMPARATOR
Intervention: Standard sterile barrier precautions (SSBP)
Number of subjects: 424
Study 19968388 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 319
Study 19968388 — intervention group
Group type: COMPARATOR
Intervention: Counseling as Usual (CAU)
Number of subjects: 319
Study 19968388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MET and CAU
Number of subjects: 319
Study 17309996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronic acid injections
Number of subjects: 11
Study 17309996 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (isotonic sodium chloride) injections
Number of subjects: 11
Study 15115710 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg every 3 days for 3 injections)
Number of subjects: 20
Study 15115710 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (observational study)
Number of subjects: 20
Study 11927728 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy in children with OSAS (N=19)
Number of subjects: 70
Study 11927728 — intervention group
Group type: COMPARATOR
Intervention: Primary snorers (PS) (N=40)
Number of subjects: 70
Study 9862512 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) alone, 18 x 10(6) IU/m2, 24-hour i.v. infusion cycles, days 1 to 4, for 25 weeks
Number of subjects: 0
Study 9862512 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) alone, 6 x 10(6) IU/m2, days 1, 3, and 5, weekly for 52 weeks
Number of subjects: 0
Study 9862512 — intervention group
Group type: COMPARATOR
Intervention: Combination of IFN and IL-2, same doses as above, for 24 weeks
Number of subjects: 0
Study 8541104 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal Lewis Y antibody (100 mg, six doses over 2 weeks)
Number of subjects: 40
Study 8541104 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen (six infusions of human serum albumin)
Number of subjects: 40
Study 2695874 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-filled vitreous cavity
Number of subjects: 51
Study 2695874 — intervention group
Group type: COMPARATOR
Intervention: Fluid-filled vitreous cavity
Number of subjects: 51
Study 900990 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft X-ray radiation
Number of subjects: 100
Study 900990 — intervention group
Group type: COMPARATOR
Intervention: Mock-radiation
Number of subjects: 100
Study 29970295 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary electronic gastric stimulation (EGS) using the Enterra™ system
Number of subjects: 6
Study 29970295 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent implantation of Enterra™ system
Number of subjects: 6
Study 29970295 — intervention group
Group type: COMPARATOR
Intervention: Non-responder group
Number of subjects: 6
Study 29970295 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary EGS system
Number of subjects: 6
Study 26564328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous aerobic exercise (30 minutes, 65%-75% heart rate reserve)
Number of subjects: 20
Study 26564328 — intervention group
Group type: COMPARATOR
Intervention: Control session (watching a cartoon)
Number of subjects: 20
Study 23932543 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated zygomatic complex fractures
Number of subjects: 283
Study 23932543 — intervention group
Group type: COMPARATOR
Intervention: Non-surgically treated zygomatic complex fractures
Number of subjects: 283
Study 22850121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 10 mg/kg/dose, administered 5 days per week for 8 weeks
Number of subjects: 531
Study 22850121 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks
Number of subjects: 531
Study 19232887 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished surface treatment
Number of subjects: 80
Study 19232887 — intervention group
Group type: COMPARATOR
Intervention: Matte surface treatment
Number of subjects: 80
Study 19232887 — intervention group
Group type: COMPARATOR
Intervention: Polymethyl methacrylate‐coated surface treatment
Number of subjects: 80
Study 17364900 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling plus group education
Number of subjects: 61
Study 17364900 — intervention group
Group type: COMPARATOR
Intervention: Individual counselling only
Number of subjects: 61
Study 16300701 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection triamcinolone acetonide with lignocaine
Number of subjects: 60
Study 16300701 — intervention group
Group type: COMPARATOR
Intervention: Injection lignocaine alone
Number of subjects: 60
Study 11950697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 1607
Study 11950697 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1607
Study 9800183 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Airways curriculum intervention
Number of subjects: 15
Study 8542460 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered sodium cromoglycate
Number of subjects: 0
Study 2611040 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (corynebacterium parvum s.c. around the scar 2 weeks after mastectomy) in node negative patients
Number of subjects: 1116
Study 2611040 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF for 1 year in node positive patients
Number of subjects: 1116
Study 2611040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immunotherapy and CMF in node positive patients
Number of subjects: 1116
Study 2611040 — intervention group
Group type: COMPARATOR
Intervention: No further adjuvant therapy in node positive patients
Number of subjects: 1116
Study 2611040 — intervention group
Group type: COMPARATOR
Intervention: No further adjuvant therapy in node negative patients
Number of subjects: 1116
Study 611325 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (30 subjects) subjected to workload tests on the bicycle ergometer, starting at a 600 kpm workload and increasing by 150 kpm each day until a heart rate near 165 bpm was reached.
Number of subjects: 60
Study 611325 — intervention group
Group type: COMPARATOR
Intervention: Validation group (30 subjects) administered the Astrand‐Rhyming Test using the established multiple regression equation to predict workload.
Number of subjects: 60
Study 30819011 — intervention group
Group type: EXPERIMENTAL
Intervention: School dropout
Number of subjects: 100
Study 30819011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 100
Study 30819011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer days of school attendance
Number of subjects: 100
Study 27707615 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning <2 hours
Number of subjects: 120
Study 27707615 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning >2 hours
Number of subjects: 120
Study 27707615 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine positioning
Number of subjects: 120
Study 27707615 — intervention group
Group type: COMPARATOR
Intervention: All groups (prone <2h, prone >2h, supine)
Number of subjects: 120
Study 25449393 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate altitude (Davos Jakobshorn at 2590 m)
Number of subjects: 0
Study 25449393 — intervention group
Group type: COMPARATOR
Intervention: Low altitude (Zurich at 490 m)
Number of subjects: 0
Study 23302544 — intervention group
Group type: COMPARATOR
Intervention: Diet-only group (DI)
Number of subjects: 48
Study 23302544 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise group (DI + EXE)
Number of subjects: 48
Study 21499770 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% added to travoprost
Number of subjects: 253
Study 21499770 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% added to travoprost
Number of subjects: 253
Study 18808335 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA priming vaccine
Number of subjects: 40
Study 18808335 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA boosting vaccine
Number of subjects: 40
Study 18808335 — intervention group
Group type: COMPARATOR
Intervention: 1 mg of HIV‐1 DNA administered intradermally
Number of subjects: 40
Study 17196045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg/day)
Number of subjects: 160
Study 17196045 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (225 mg/day)
Number of subjects: 160
Study 17196045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg/day) at maximum dose for 3 weeks
Number of subjects: 160
Study 17196045 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (225 mg/day) at maximum dose for 3 weeks
Number of subjects: 160
Study 12689612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine administration
Number of subjects: 0
Study 12689612 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 10611186 — intervention group
Group type: EXPERIMENTAL
Intervention: Long GnRHa/HMG protocol with luteal support by repeated HCG (n = 20)
Number of subjects: 60
Study 10611186 — intervention group
Group type: EXPERIMENTAL
Intervention: Early follicular phase cessation of GnRHa without luteal support (n = 20)
Number of subjects: 60
Study 10611186 — intervention group
Group type: EXPERIMENTAL
Intervention: Long GnRHa protocol without luteal support (n = 20)
Number of subjects: 60
Study 10611186 — intervention group
Group type: COMPARATOR
Intervention: Control group of 40 normo-ovulatory women
Number of subjects: 60
Study 9194725 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 5 or more drusen
Number of subjects: 670
Study 9194725 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal hyperpigmentation
Number of subjects: 670
Study 9194725 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 1 or more large drusen
Number of subjects: 670
Study 9194725 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite systemic hypertension
Number of subjects: 670
Study 9194725 — intervention group
Group type: COMPARATOR
Intervention: No risk factors
Number of subjects: 670
Study 9194725 — intervention group
Group type: EXPERIMENTAL
Intervention: All 4 risk factors present
Number of subjects: 670
Study 8184498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive back training
Number of subjects: 96
Study 8184498 — intervention group
Group type: COMPARATOR
Intervention: Traditional back training
Number of subjects: 96
Study 2440159 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml Pentastarch
Number of subjects: 12
Study 2440159 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml Pentastarch
Number of subjects: 12
Study 2440159 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ml Pentastarch
Number of subjects: 12
Study 29673974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 61
Study 29673974 — intervention group
Group type: COMPARATOR
Intervention: Supportive Care (SC)
Number of subjects: 61
Study 25047162 — intervention group
Group type: EXPERIMENTAL
Intervention: Translig transverse crosspin
Number of subjects: 118
Study 25047162 — intervention group
Group type: COMPARATOR
Intervention: ToggleLoc with ZipLoop technology
Number of subjects: 118
Study 22893231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay for performance (P4P) condition
Number of subjects: 986
Study 22893231 — intervention group
Group type: COMPARATOR
Intervention: Implementation-as-usual (IAU) control condition
Number of subjects: 986
Study 20528891 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone (AB) chips
Number of subjects: 92
Study 20528891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossix membrane (OM)
Number of subjects: 92
Study 20528891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AB chips and OM
Number of subjects: 92
Study 20528891 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 92
Study 20528891 — intervention group
Group type: COMPARATOR
Intervention: Younger patients (<50 years)
Number of subjects: 92
Study 18826532 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check‐Up and linked parenting support services
Number of subjects: 731
Study 15910157 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel word labeling with conceptual descriptions (artifacts and animates)
Number of subjects: 2
Study 15910157 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel word labeling with conceptual descriptions
Number of subjects: 2
Study 12873912 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% DCLHb (n = 92)
Number of subjects: 181
Study 12873912 — intervention group
Group type: COMPARATOR
Intervention: 3 U of packed red blood cells (PRBCs) (n = 89)
Number of subjects: 181
Study 10392982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management (case load 10-15 per case manager)
Number of subjects: 708
Study 10392982 — intervention group
Group type: COMPARATOR
Intervention: Standard case management (case load 30-35 per case manager)
Number of subjects: 708
Study 7727091 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic tympanostomy tubes impregnated with silver oxide
Number of subjects: 125
Study 7727091 — intervention group
Group type: COMPARATOR
Intervention: Control ears with standard Silastic tubes
Number of subjects: 125
Study 2104531 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone cream with 20% silicone oil and occlusive dressing technique
Number of subjects: 47
Study 2104531 — intervention group
Group type: COMPARATOR
Intervention: Simple application of silicone cream
Number of subjects: 47
Study 6997360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% proparacaine
Number of subjects: 361
Study 6997360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% benoxinate
Number of subjects: 361
Study 6997360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% proparacaine
Number of subjects: 361
Study 6997360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of anesthetic
Number of subjects: 361
Study 31030100 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO + THD
Number of subjects: 17
Study 31030100 — intervention group
Group type: EXPERIMENTAL
Intervention: THD monotherapy
Number of subjects: 17
Study 29234055 — intervention group
Group type: EXPERIMENTAL
Intervention: OIT combined with 24 weeks of omalizumab (OMB)
Number of subjects: 16
Study 29234055 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 16
Study 25597862 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 4 mg once daily
Number of subjects: 268
Study 25597862 — intervention group
Group type: COMPARATOR
Intervention: Silodosin 4 mg twice daily
Number of subjects: 268
Study 22841433 — intervention group
Group type: EXPERIMENTAL
Intervention: Description condition (payoff matrix)
Number of subjects: 0
Study 22841433 — intervention group
Group type: COMPARATOR
Intervention: Experience condition (learned payoffs through experience)
Number of subjects: 0
Study 22841433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergroup Prisoner's Dilemma with Intragroup Power Dynamics
Number of subjects: 0
Study 21161265 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT + usual care (n = 24)
Number of subjects: 49
Study 21161265 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (n = 25)
Number of subjects: 49
Study 21161265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 49
Study 19531419 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g amoxicillin tablets 1 hour before surgery
Number of subjects: 59
Study 19531419 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy (Control)
Number of subjects: 59
Study 16754935 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 632
Study 16754935 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 632
Study 16754935 — intervention group
Group type: EXPERIMENTAL
Intervention: MR (maintenance rituximab)
Number of subjects: 632
Study 16754935 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 632
Study 16754935 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP + MR
Number of subjects: 632
Study 16754935 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP + MR
Number of subjects: 632
Study 15111272 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS (dioctyl sodium sulfosuccinate) applied topically every 2 hours during outbreaks
Number of subjects: 32
Study 15111272 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied topically every 2 hours during outbreaks
Number of subjects: 32
Study 11696709 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous stone removal
Number of subjects: 128
Study 11696709 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy
Number of subjects: 128
Study 9156038 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (100 micrograms i.v.)
Number of subjects: 21
Study 9156038 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 (1 microgram/kg i.v.)
Number of subjects: 21
Study 9156038 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-6
Number of subjects: 21
Study 7828613 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-slice rectangular ROIs in frontal, temporal, temporoparietal, and occipital cortices
Number of subjects: 108
Study 7828613 — intervention group
Group type: COMPARATOR
Intervention: Single-slice and multi-slice ROIs with reference to normal anatomy
Number of subjects: 108
Study 7828613 — intervention group
Group type: EXPERIMENTAL
Intervention: SPET using technetium‐99m d,l‐hexamethylpropylene amine oxime (99mTc‐HMPAO)
Number of subjects: 108
Study 7828613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular ROIs
Number of subjects: 108
Study 3341336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 3
Study 3341336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 3
Study 3341336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg
Number of subjects: 3
Study 3341336 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 3
Study 3341336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine vs. Cimetidine
Number of subjects: 3
Study 3341336 — intervention group
Group type: EXPERIMENTAL
Intervention: ADU vs. IDU
Number of subjects: 3
Study 31656059 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO-guided algorithm (inhaled corticosteroid (ICS) dose adjusted according to FENO with long-acting beta-agonist (LABA) added for uncontrolled symptoms)
Number of subjects: 220
Study 31656059 — intervention group
Group type: COMPARATOR
Intervention: Symptom control algorithm (control group)
Number of subjects: 220
Study 29986662 — intervention group
Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 1200
Study 29986662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial brochure
Number of subjects: 1200
Study 28557903 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 70
Study 26136594 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum 25(OH)D concentrations
Number of subjects: 217
Study 26136594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower plasma glucose concentrations
Number of subjects: 217
Study 26136594 — intervention group
Group type: COMPARATOR
Intervention: Serum 25(OH)D and plasma insulin concentrations
Number of subjects: 217
Study 26136594 — intervention group
Group type: COMPARATOR
Intervention: Plasma glucose
Number of subjects: 217
Study 23532808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeper One(®)
Number of subjects: 112
Study 23532808 — intervention group
Group type: COMPARATOR
Intervention: WAND(®)
Number of subjects: 112
Study 20929998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with olive oil (1 liter/week)
Number of subjects: 418
Study 20929998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with nuts (30 g/day)
Number of subjects: 418
Study 20929998 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-fat diet)
Number of subjects: 418
Study 20929998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Mediterranean diets (with olive oil and nuts)
Number of subjects: 418
Study 17678911 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (75-150 IU/d) + GnRH antagonist (0.25 mg/d)
Number of subjects: 367
Study 17678911 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH (75-150 IU/d) alone
Number of subjects: 367
Study 16573259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream plus clindamycin 1%/benzoyl peroxide 5% gel
Number of subjects: 0
Study 16573259 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene 0.1% cream
Number of subjects: 0
Study 14574651 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe smoke inhalation cases
Number of subjects: 22
Study 14574651 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 22
Study 14574651 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cases to controls
Number of subjects: 22
Study 10764848 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting visual acuity
Number of subjects: 0
Study 10764848 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity
Number of subjects: 0
Study 10764848 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 0
Study 10764848 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive error under cycloplegia
Number of subjects: 0